Understanding Frontline ABVD in the Real World
Consult QD
JUNE 9, 2023
Although frontline treatment for classical Hodgkin’s lymphoma (cHL) is intended to be curative, a surprisingly high percentage of patients treated in the community setting receive subsequent therapy. This is one of many issues raised from a retrospective analysis of patients treated with ABVD in the real-world setting. Background In 2018, the RATHL study demonstrated that patients with advanced stage cHL could be treated with ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) for two cyc
Let's personalize your content